Concepedia

Jamie Shaw

JS

Statistics

Publications

8

Citations

200

H-Index

8

Active since

2010

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Ono Pharmaceutical (United States)

Merck Serono S.A. (Switzerland)

The University of Texas MD Anderson Cancer Center

Merck Serono S.p.A. (Italy)

Jamie Shaw is an author at Merck KGaA, Darmstadt (Germany) specializing in pharmacology, clinical pharmacology, and inflammatory cytokine secretion.

ORCID

Publications per year

2010–2024

8

Publications

8

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

Andreas Port, Jamie Shaw, Lena Klopp‐Schulze et al. · Pharmacology Research & Perspectives · 2021 · 54 citations · Full text

, , +10

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Apostolia M. Tsimberidou, Jamie Shaw, Dejan Juric et al. · Journal of Hematology & Oncology · 2021 · 29 citations · Full text

, , +16

The Use of Sentinel Lymph Node Biopsy in Ductal Carcinoma in Situ

Christopher Schneider, Steven D. Trocha, Brian McKinley et al. · The American Surgeon · 2010 · 29 citations

, , +15

AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology

Apostolia M. Tsimberidou, Antonis Skliris, Alan Valentine et al. · Cell & Bioscience · 2022 · 22 citations · Full text

, , +17

Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

Lena Klopp‐Schulze, Sathej Gopalakrishnan, Özkan Yalkinoglu et al. · Clinical Pharmacology & Therapeutics · 2024 · 21 citations · Full text

, , +17

1–5 of 8